WASHINGTON D.C. (October 14, 2022) -- The Association for Accessible Medicines (AAM) and its Biosimilars Council commend today's Executive Order.
“It is critical that the Administration take steps to address the perverse incentives created by brand drug rebates that undermine adoption of lower cost generics and biosimilars,” said Craig Burton, Executive Director of the Biosimilars Council and Senior Vice President of Policy & Strategic Alliances at AAM. “We stand ready to work with HHS on our shared goal of reducing the costs of prescription drugs for patients."
MEDIA CONTACT:
Susan Reilly
Director of Communications, AAM
1.703.725.0729
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 91 percent of prescriptions dispensed in the U.S. but only 18 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.